Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8714621 | 0.81 | LIPE (0.57) | LIPESMN1; SMN2CYP2D6ALDH1A1TSHR | |
| SCHEMBL7206184 | 0.81 | LIPE (0.47) | LIPESMN1; SMN2ALDH1A1 | |
| SCHEMBL8939929 | 0.79 | LIPE (0.48) | LIPESMN1; SMN2CA12CA1CA2 | |
| SCHEMBL10703372 | 0.75 | SMN1; SMN2 (0.46) | LIPESMN1; SMN2CA12CA1CA2 | |
| SCHEMBL28242343 | 0.75 | LIPE (0.50) | LIPESMN1; SMN2CA12CA1CA2 | |
| SCHEMBL8586849 | 0.74 | EPHX1 (0.51) | LIPESMN1; SMN2 | |
| SCHEMBL910451 | 0.73 | LIPE (0.53) | LIPESMN1; SMN2CA12CA1CA2 | |
| SCHEMBL27461589 | 0.71 | LIPE (0.45) | LIPESMN1; SMN2CA12CA1CA2 | |
| SCHEMBL365772 | 0.71 | EPHX2 (0.53) | LIPESMN1; SMN2CA12CA1CA2 | |
| SCHEMBL2914249 | 0.71 | TSHR (0.66) | SMN1; SMN2CA12CA1CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE38333-E1 | Making tenofovir analogs and salts; use as viricides for HIV, retroviruses | GILEAD SCIENCES, INC. | 2003-11-25 | — | — | US | disclosed |
| EP-0915894-B1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES INC (US) | 2003-05-14 | — | — | EP | disclosed |
| US-6069249-A | CHEMICAL INTERMEDIATES; DETECTION LABELS FOR NUCLEOTIDE PROBES | GILEAD SCIENCES, INC. (US) | 2000-05-30 | — | — | US | disclosed |
| US-6043230-A | Use of tenofovir disoproxil fumarate in treatment of HIV | GILEAD SCIENCES, INC. (US) | 2000-03-28 | — | — | US | disclosed |
| US-5977089-A | ORALLY ADMINISTERING TENOFOVIR DERIVATIVES | GILEAD SCIENCES, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5922695-A | COMPOUNDS CONTAINING CARBONATE OR CARBAMATE GROUPS | GILEAD SCIENCES, INC. (US) | 1999-07-13 | — | — | US | disclosed |
| EP-0915894-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998004569-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1998-02-05 | — | — | WO | disclosed |